Dimerix CEO explains company’s different drug combo R&D strategy

December 6, 2016 Christoph Graener

 

Global director of content for Informa Pharma Intelligence, Mike Ward, talks to Kathy Harrison, CEO of Australian biotech Dimerix, about the company’s unusual business model. They discuss Dimerix’s Receptor-Heteromer Investigation Technology (HIT) platform and how it is used by the company and its partners. Dimerix’s pipeline is based on combining existing therapies with new drugs, a system it believes helps to lower risk to the company during the R&D phase. Dimerix’s lead compound is DMX-200, a Phase II chronic kidney disease treatment. DMX-200 is a combination of two existing drugs, irbesartan and propagermanium, which are already on the market in various regions around the world.


Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Kathy Harrison – CEO, Dimerix

 

Previous Article
Peter Fong on Genentech’s science shopping list, recent BioNtech deal
Peter Fong on Genentech’s science shopping list, recent BioNtech deal

Peter Fong explains Genentech's oncology focus, seeking the best science and how a typical biotech deal wor...

Next Article
How are regulatory changes affecting early stage R&D in China?
How are regulatory changes affecting early stage R&D in China?

Darren Ji discusses the recent crackdown on clinical data quality by the China FDA and regulatory changes f...